Evidence map›Paper›PMID 40867303›Full record

ArticleCancers2025

Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology.

Susann Schulze, Sabrina Jotschke, Robby Engelmann, Beatrice Ludwig-Kraus, Frank Bernhard Kraus, Nadja Jaekel, Christina Zahn, Christian Junghanss, Sebastian Böttcher, Haifa Kathrin Al-Ali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Susann SchulzeKrukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.ORCID 0000-0002-3856-7956
Sabrina JotschkeKrukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.
Robby EngelmannClinic III-Hematology, Oncology, and Palliative Care, Rostock University Medical Center, 18057 Rostock, Germany.ORCID 0000-0002-1048-3638
Beatrice Ludwig-KrausDepartment of Laboratory Medicine, Unit II LM-CC, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.ORCID 0000-0003-2660-4921
Frank Bernhard KrausDepartment of Laboratory Medicine, Unit II LM-CC, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.ORCID 0000-0003-4354-9952
Nadja JaekelUniversity Clinic and Outpatient Clinic for Internal Medicine IV, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.ORCID 0000-0001-6162-515X
Christina ZahnKrukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.
Christian JunghanssClinic III-Hematology, Oncology, and Palliative Care, Rostock University Medical Center, 18057 Rostock, Germany.
Sebastian BöttcherClinic III-Hematology, Oncology, and Palliative Care, Rostock University Medical Center, 18057 Rostock, Germany.ORCID 0000-0002-3603-761X
Haifa Kathrin Al-AliKrukenberg Cancer Center Halle, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.ORCID 0000-0001-5009-2239

Funding

East German Study Group for Hematology and Oncology (OSHO) NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-spike-IgGCD4+-cellsCD8+-cellshematologic malignancieslong-term immune responselymphoid neoplasmsmyeloid neoplasmsSARS-CoV-2 vaccinationT-cells

Identifiers

PMID40867303
PMCPMC12384667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.